Main Article Content


Epilepsy is one of the most common neurological disorders to affect children, and has its highest incidence in infancy. Approximately one-quarter of children have seizures which are drug-resistant, and place the child at increased risk of cognitive delays, attention, behavior and psychiatric disorders, injury, sudden unexpected death and poor quality of life. This article presents a rational approach to the investigation and management of children with drug-resistant epilepsy.




Drug resistant epilepsy epilepsy surgery ketogenic diet

Article Details

How to Cite
Wirrell, E. (2021). Rational Approach to Children with Drug-Resistant Epilepsy: Drug Resistant Childhood Epilepsy. Journal of the International Child Neurology Association, 1(1).


    1. Camfield CS, Camfield PR, Gordon K, Wirrell E, Dooley JM. Incidence of epilepsy in childhood and adolescence: a population-based study in Nova Scotia from 1977 to 1985. Epilepsia. 1996;37(1):19-23.
    2. Wirrell EC, Grossardt BR, Wong-Kisiel LC, Nickels KC. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study. Epilepsy Res. 2011;95(1-2):110-8.
    3. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77.
    4. Berg AT. Defining intractable epilepsy. Adv Neurol. 2006;97:5-10.
    5. Wirrell EC. Predicting pharmacoresistance in pediatric epilepsy. Epilepsia. 2013;54 Suppl 2:19-22.
    6. Kotagal P, Costa M, Wyllie E, Wolgamuth B. Paroxysmal nonepileptic events in children and adolescents. Pediatrics. 2002;110(4):e46.
    7. Park EG, Lee J, Lee BL, Lee M, Lee J. Paroxysmal nonepileptic events in pediatric patients. Epilepsy Behav. 2015;48:83-7.
    8. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512-21.
    9. Gayatri NA, Livingston JH. Aggravation of epilepsy by anti-epileptic drugs. Dev Med Child Neurol. 2006;48(5):394-8.
    10. Gelisse P, Genton P, Kuate C, Pesenti A, Baldy-Moulinier M, Crespel A. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia. 2004;45(10):1282-6.
    11. Sazgar M, Bourgeois BF. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol. 2005;33(4):227-34.
    12. Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain. 2006;129(Pt 5):1281-92.
    13. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39(1):5-17.
    14. Knake S, Hamer HM, Schomburg U, Oertel WH, Rosenow F. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure. 1999;8(5):314-7.
    15. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39(5):508-12.
    16. Dhamija R, Moseley BD, Cascino GD, Wirrell EC. A population-based study of long-term outcome of epilepsy in childhood with a focal or hemispheric lesion on neuroimaging. Epilepsia. 2011;52(8):1522-6.
    17. Yildiz EP, Gunes D, Bektas G, Aksu Uzunhan T, Tatli B, Caliskan M, et al. Predictive factors of drug-resistant epilepsy in children presenting under 2 years of age: experience of a tertiary center in Turkey. Acta Neurol Belg. 2018;118(1):71-5.
    18. Wirrell EC, Wong-Kisiel LC, Mandrekar J, Nickels KC. What predicts enduring intractability in children who appear medically intractable in the first 2 years after diagnosis? Epilepsia. 2013;54(6):1056-64.
    19. Moosa AN, Wyllie E. Focal epileptogenic lesions. Handb Clin Neurol. 2013;111:493-510.
    20. Wirrell E, Wong-Kisiel L, Mandrekar J, Nickels K. Predictors and course of medically intractable epilepsy in young children presenting before 36 months of age: a retrospective, population-based study. Epilepsia. 2012;53(9):1563-9.
    21. Mohamed A, Wyllie E, Ruggieri P, Kotagal P, Babb T, Hilbig A, et al. Temporal lobe epilepsy due to hippocampal sclerosis in pediatric candidates for epilepsy surgery. Neurology. 2001;56(12):1643-9.
    22. Loddenkemper T, Cosmo G, Kotagal P, Haut J, Klaas P, Gupta A, et al. Epilepsy surgery in children with electrical status epilepticus in sleep. Neurosurgery. 2009;64(2):328-37; discussion 37.
    23. Hnojcikova M, Nickels KC, Wetjen NM, Buchhalter JR, Raffel C, Wirrell EC. EEG and neuroimaging studies in young children having epilepsy surgery. Pediatr Neurol. 2010;43(5):335-40.
    24. Saneto RP, Wyllie E. Epilepsy surgery in infancy. Semin Pediatr Neurol. 2000;7(3):187-93.
    25. Gowda S, Salazar F, Bingaman WE, Kotagal P, Lachhwani DL, Gupta A, et al. Surgery for catastrophic epilepsy in infants 6 months of age and younger. J Neurosurg Pediatr. 2010;5(6):603-7.
    26. Wyllie E. Surgery for catastrophic localization-related epilepsy in infants. Epilepsia. 1996;37 Suppl 1:S22-5.
    27. Pearl PL. Amenable Treatable Severe Pediatric Epilepsies. Semin Pediatr Neurol. 2016;23(2):158-66.
    28. Shellhaas RA, Wusthoff CJ, Tsuchida TN, Glass HC, Chu CJ, Massey SL, et al. Profile of neonatal epilepsies: Characteristics of a prospective US cohort. Neurology. 2017;89(9):893-9.
    29. Berg AT, Coryell J, Saneto RP, Grinspan ZM, Alexander JJ, Kekis M, et al. Early-Life Epilepsies and the Emerging Role of Genetic Testing. JAMA Pediatr. 2017;171(9):863-71.
    30. Axeen EJT, Olson HE. Neonatal epilepsy genetics. Semin Fetal Neonatal Med. 2018;23(3):197-203.
    31. Coryell J, Gaillard WD, Shellhaas RA, Grinspan ZM, Wirrell EC, Knupp KG, et al. Neuroimaging of Early Life Epilepsy. Pediatrics. 2018;142(3).
    32. Suleiman J, Brilot F, Lang B, Vincent A, Dale RC. Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia. 2013;54(6):1036-45.
    33. Suleiman J, Dale RC. The recognition and treatment of autoimmune epilepsy in children. Dev Med Child Neurol. 2015;57(5):431-40.
    34. Wong-Kisiel LC, McKeon A, Wirrell EC. Autoimmune encephalopathies and epilepsies in children and teenagers. Can J Neurol Sci. 2012;39(2):134-44.
    35. Korff CM, Dale RC. The Immune System in Pediatric Seizures and Epilepsies. Pediatrics. 2017;140(3).
    36. Toledano M, Britton JW, McKeon A, Shin C, Lennon VA, Quek AM, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014;82(18):1578-86.
    37. Eyre M, Hacohen Y, Lamb K, Absoud M, Agrawal S, Gadian J, et al. Utility and safety of plasma exchange in paediatric neuroimmune disorders. Dev Med Child Neurol. 2019;61(5):540-6.
    38. Aso K, Watanabe K. Limitations in the medical treatment of cryptogenic or symptomatic localization-related epilepsies of childhood onset. Epilepsia. 2000;41 Suppl 9:18-20.
    39. Wirrell EC, Wong-Kisiel LC, Nickels KC. Seizure outcome after AED failure in pediatric focal epilepsy: impact of underlying etiology. Epilepsy Behav. 2014;34:20-4.
    40. Wirrell E, Camfield C, Camfield P, Dooley J. Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy. Epilepsia. 2001;42(6):760-3.
    41. Wheless JW. History of the ketogenic diet. Epilepsia. 2008;49 Suppl 8:3-5.
    42. Kossoff EH, Dorward JL. The modified Atkins diet. Epilepsia. 2008;49 Suppl 8:37-41.
    43. Pfeifer HH, Thiele EA. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. Neurology. 2005;65(11):1810-2.
    44. Kim JA, Yoon JR, Lee EJ, Lee JS, Kim JT, Kim HD, et al. Efficacy of the classic ketogenic and the modified Atkins diets in refractory childhood epilepsy. Epilepsia. 2016;57(1):51-8.
    45. Kossoff EH, Zupec-Kania BA, Amark PE, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia. 2009;50(2):304-17.
    46. Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018;3(2):175-92.
    47. Ciliberto MA, Limbrick D, Powers A, Titus JB, Munro R, Smyth MD. Palliative hemispherotomy in children with bilateral seizure onset. J Neurosurg Pediatr. 2012;9(4):381-8.
    48. Ilyas M, Sivaswamy L, Asano E, Sood S, Zidan M, Chugani H. Seizure control following palliative resective surgery for intractable epilepsy-a pilot study. Pediatr Neurol. 2014;51(3):330-5.
    49. Chan AY, Rolston JD, Lee B, Vadera S, Englot DJ. Rates and predictors of seizure outcome after corpus callosotomy for drug-resistant epilepsy: a meta-analysis. J Neurosurg. 2018:1-10.
    50. Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A. Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations. Front Neurol. 2017;8:505.
    51. Wheless JW, Gienapp AJ, Ryvlin P. Vagus nerve stimulation (VNS) therapy update. Epilepsy Behav. 2018;88S:2-10.
    52. Geller EB. Responsive neurostimulation: Review of clinical trials and insights into focal epilepsy. Epilepsy Behav. 2018;88S:11-20.
    53. Salanova V, Witt T, Worth R, Henry TR, Gross RE, Nazzaro JM, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology. 2015;84(10):1017-25.
    54. Yan H, Toyota E, Anderson M, Abel TJ, Donner E, Kalia SK, et al. A systematic review of deep brain stimulation for the treatment of drug-resistant epilepsy in childhood. J Neurosurg Pediatr. 2018;23(3):274-84.